|
1
|
Liu Y, Kanyomse Q and Xie Y:
Tumor-suppressive activity of Hnf1β in Wilms' tumor. Biosci
Biotechnol Biochem. 83:2008–2015. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Suzuki E, Kajita S, Takahashi H, Matsumoto
T, Tsuruta T and Saegusa M: Transcriptional upregulation of HNF-1β
by NF-KB in ovarian clear cell carcinoma modulates susceptibility
to apoptosis through alteration in bcl-2 expression. Lab Invest.
95:962–972. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tsuchiya A, Sakamoto M, Yasuda J, Chuma M,
Ohta T, Ohki M, Yasugi T, Taketani Y and Hirohashi S: Expression
profiling in ovarian clear cell carcinoma: Identification of
hepatocyte nuclear factor-1 beta as a molecular marker and a
possible molecular target for therapy of ovarian clear cell
carcinoma. Am J Pathol. 163:2503–2512. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartu M, Dundr P, Nemejcova K, Ticha I,
Hojny H and Hajkova N: The role of HNF1B in tumorigenesis of solid
tumours: A review of current knowledge. Folia Biol (Praha).
64:71–83. 2018.PubMed/NCBI
|
|
5
|
Ross-Adams H, Ball S, Lawrenson K, Halim
S, Russell R, Wells C, Strand SH, Ørntoft TF, Larson M, Armasu S,
et al: HNF1B variants associate with promoter methylation and
regulate gene networks activated in prostate and ovarian cancer.
Oncotarget. 7:74734–74746. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matsui A, Fujimoto J, Ishikawa K, Ito E,
Goshima N, Watanabe S and Semba K: Hepatocyte nuclear factor 1 beta
induces transformation and epithelial-to-mesenchymal transition.
FEBS Lett. 590:1211–1221. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kato N, Sasou S and Motoyama T: Expression
of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors
and endometriosis of the ovary. Mod Pathol. 19:83–89. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mandato VD, Farnetti E, Torricelli F,
Abrate M, Casali B, Ciarlini G, Pirillo D, Gelli MC, Nicoli D,
Grassi M, et al: HNF1B polymorphism influences the prognosis of
endometrial cancer patients: A cohort study. BMC Cancer.
15:2292015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Setiawan VW, Haessler J, Schumacher F,
Cote ML, Deelman E, Fesinmeyer MD, Henderson BE, Jackson RD,
Vöckler JS, Wilkens LR, et al: HNF1B and endometrial cancer risk:
Results from the PAGE study. PLoS One. 7:e303902012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shen H, Fridley BL, Song H, Lawrenson K,
Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, et
al: Epigenetic analysis leads to identification of HNF1B as a
subtype-specific susceptibility gene for ovarian cancer. Nat
Commun. 4:16282013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Spurdle AB, Thompson DJ, Ahmed S, Ferguson
K, Healey CS, O'Mara T, Walker LC, Montgomery SB, Dermitzakis ET;
Australian National Endometrial Cancer Study Group, ; et al:
Genome-wide association study identifies a common variant
associated with risk of endometrial cancer. Nat Genet. 43:451–454.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kato N and Motoyama T: Hepatocyte nuclear
factor-1beta (HNF-1beta) in human urogenital organs: Its expression
and role in embryogenesis and tumorigenesis. Histol Histopathol.
24:1479–1486. 2009.PubMed/NCBI
|
|
13
|
Yamamoto S, Tsuda H, Aida S, Shimazaki H,
Tamai S and Matsubara O: Immunohistochemical detection of
hepatocyte nuclear factor 1beta in ovarian and endometrial
clear-cell adenocarcinomas and nonneoplastic endometrium. Hum
Pathol. 38:1074–1080. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fadare O and Liang SX: Diagnostic utility
of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial
carcinomas: Lack of specificity for endometrial clear cell
carcinoma. Appl Immunohistochem Mol Morphol. 20:580–587. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kao YC, Lin MC, Lin WC, Jeng YM and Mao
TL: Utility of hepatocyte nuclear factor-1β as a diagnostic marker
in ovarian carcinomas with clear cells. Histopathology. 61:760–768.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nemejcova K, Ticha I, Kleiblova P, Bártů
M, Cibula D, Jirsová K and Dundr P: Expression, epigenetic and
genetic changes of HNF1B in endometrial lesions. Pathol Oncol Res.
22:523–530. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dan C, Zhang H, Zeng W, Huang L, Gong X,
Li H, Yang E, Wang L and Yao Q: HNF1B expression regulates ECI2
gene expression, potentially serving a role in prostate cancer
progression. Oncol Lett. 17:1094–1100. 2019.PubMed/NCBI
|
|
18
|
Houten SM, Violante S, Ventura FV and
Wanders RJ: The biochemistry and physiology of mitochondrial fatty
acid β-oxidation and its genetic disorders. Annu Rev Physiol.
78:23–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Itkonen HM, Brown M, Urbanucci A, Tredwell
G, Ho Lau C, Barfeld S, Hart C, Guldvik IJ, Takhar M, Heemers HV,
et al: Lipid degradation promotes prostate cancer cell survival.
Oncotarget. 8:38264–38275. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fan J, Li X, Issop L, Culty M and
Papadopoulos V: ACBD2/ECI2-mediated peroxisome-mitochondria
interactions in leydig cell steroid biosynthesis. Mol Endocrinol.
30:763–782. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hirsch FR, Dziadziuszko R, Thatcher N,
Mann H, Watkins C, Parums DV, Speake G, Holloway B, Bunn PA Jr and
Franklin WA: Epidermal growth factor receptor immunohistochemistry:
Comparison of antibodies and cutoff points to predict benefit from
gefitinib in a phase 3 placebo-controlled study in advanced
nonsmall-cell lung cancer. Cancer. 112:1114–1121. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bartu M, Hojny J, Hajkova N, Michálková R,
Krkavcová E, Simon K, Frýba V, Stružinská I, Němejcová K and Dundr
P: Expression, epigenetic, and genetic changes of HNF1B in
colorectal lesions: An analysis of 145 cases. Pathol Oncol Res.
26:2337–2350. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dundr P, Bartu M, Hojny J, Michálková R,
Hájková N, Stružinská I, Krkavcová E, Hadravský L, Kleissnerová L,
Kopejsková J, et al: HNF1B, EZH2 and ECI2 in prostate carcinoma.
Molecular, immunohistochemical and clinico-pathological study. Sci
Rep. 10:143652020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim HY: Statistical notes for clinical
researchers: Chi-squared test and Fisher's exact test. Restor Dent
Endod. 42:152–155. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cancer Genome Atlas Research Network, .
The molecular taxonomy of primary prostate cancer. Cell.
163:1011–1025. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kato N, Tamura G and Motoyama T:
Hypomethylation of hepatocyte nuclear factor-1beta (HNF-1beta) CpG
island in clear cell carcinoma of the ovary. Virchows Arch.
452:175–180. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lau HH, Ng NHJ, Loo LSW, Jasmen JB and Teo
AKK: The molecular functions of hepatocyte nuclear factors-In and
beyond the liver. J Hepatol. 68:1033–1048. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kalloger SE, Kobel M, Leung S, Mehl E, Gao
D, Marcon KM, Chow C, Clarke BA, Huntsman DG and Gilks CB:
Calculator for ovarian carcinoma subtype prediction. Mod Pathol.
24:512–521. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tomassetti A, De Santis G, Castellano G,
Miotti S, Mazzi M, Tomasoni D, Van Roy F, Carcangiu ML and Canevari
S: Variant HNF1 modulates epithelial plasticity of normal and
transformed ovary cells. Neoplasia. 10:1481–1492. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ,
Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, et
al: Rethinking ovarian cancer II: Reducing mortality from
high-grade serous ovarian cancer. Nat Rev Cancer. 15:668–679. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Terasawa K, Toyota M, Sagae S, Ogi K,
Suzuki H, Sonoda T, Akino K, Maruyama R, Nishikawa N, Imai K, et
al: Epigenetic inactivation of TCF2 in ovarian cancer and various
cancer cell lines. Br J Cancer. 94:914–921. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bubancova I, Kovarikova H, Laco J, Ruszova
E, Dvorak O, Palicka V and Chmelarova M: Next-generation sequencing
approach in methylation analysis of HNF1B and GATA4 genes:
Searching for biomarkers in ovarian cancer. Int J Mol Sci.
18:4742017. View Article : Google Scholar
|
|
33
|
Baranova I, Kovarikova H, Laco J,
Sedlakova I, Vrbacky F, Kovarik D, Hejna P, Palicka V and
Chmelarova M: Identification of a four-gene methylation biomarker
panel in high-grade serous ovarian carcinoma. Clin Chem Lab Med.
58:1332–1340. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chaffer CL, San Juan BP, Lim E and
Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis
Rev. 35:645–654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang W, Cheng X, Ji J, Zhang J and Li Q:
The application value of HNF-1β transcription factor in the
diagnosis of ovarian clear cell carcinoma. Int J Gynecol Pathol.
35:66–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kobel M, Kalloger SE, Carrick J, Huntsman
D, Asad H, Oliva E, Ewanowich CA, Soslow RA and Gilks CB: A limited
panel of immunomarkers can reliably distinguish between clear cell
and high-grade serous carcinoma of the ovary. Am J Surg Pathol.
33:14–21. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li Q, Zeng X, Cheng X, Zhang J, Ji J, Wang
J, Xiong K, Qi Q and Huang W: Diagnostic value of dual detection of
hepatocyte nuclear factor 1 beta (HNF-1β) and napsin A for
diagnosing ovarian clear cell carcinoma. Int J Clin Exp Pathol.
8:8305–8310. 2015.PubMed/NCBI
|
